Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E.W. Cohen, Signe Friesland, Ainara Soria et al.|The Lancet|2018Cited by 1.7k
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trialHisham Mehanna, Mererid Evans|The Lancet|2018Cited by 1k
Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus StatementDavid Thomson, Sue S. Yom, David A. Palma et al.|International Journal of Radiation Oncology*Biology*Physics|2020Cited by 211